Retatrutide + Cagrilintide Peptide Stack

This synergistic stack combines Retatrutide (a metabolic triple agonist) and Cagrilintide (an amylin analog), both of which target distinct yet complementary mechanisms involved in appetite regulation and metabolic control. Research indicates that while incretin-based therapies like GLP-1 agonists primarily engage the gut-brain axis to influence satiety, amylin receptor agonism operates via separate pathways, particularly in the hindbrain. This dual approach is gaining traction in clinical trials as it may enhance overall efficacy in weight management strategies, particularly for individuals with obesity or related metabolic disorders.

Retatrutide is an innovative investigational agent developed by Eli Lilly, acting as a triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors. In the Phase 2 trial led by Jastreboff et al. (2023), participants receiving a 12 mg dose experienced a mean body weight reduction of 24.2% over 48 weeks, with all subjects achieving at least a 5% weight loss. Ongoing Phase 3 trials, particularly the TRIUMPH series, are expected to further elucidate its efficacy, with TRIUMPH-4 anticipated to report significant outcomes, including weight loss and improvements in osteoarthritis symptoms by December 2025. The FDA is expected to review its application for approval in 2027-2028. Retatrutide's mechanism involves the simultaneous activation of three receptors: GLP-1 reduces appetite and slows gastric emptying, GIP enhances insulin sensitivity, and glucagon increases energy expenditure. This triadic synergy sets it apart from dual agonists, such as tirzepatide, by adding a glucagon-mediated thermogenic effect.

Cagrilintide is a synthetic analog of human amylin, developed by Novo Nordisk. This peptide hormone is co-secreted with insulin and plays a crucial role in regulating appetite and glucose metabolism. Cagrilintide is being investigated both as a standalone treatment and in combination with semaglutide, branded as CagriSema. Clinical data from the REDEFINE Phase 3 program indicate that CagriSema can achieve an average weight loss of 20.4% over 68 weeks, with regulatory submission expected in 2026. The mechanism of Cagrilintide involves the activation of amylin receptors in the hindbrain, which promotes satiety through pathways distinct from those engaged by GLP-1 agonists. By slowing gastric emptying and modulating glucagon release, Cagrilintide enhances meal-related satiety. Its structural modifications, including a fatty acid side chain, extend its half-life to approximately one week, facilitating once-weekly administration. The combination with semaglutide in CagriSema exemplifies how targeting multiple satiety pathways can yield greater weight loss than either compound alone.